The Latest Cardiac and Vascular News
The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is the first randomized controlled trial (RCT) comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies […]
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the appointment of Axel-Sven Malkomes as Chief Financial Officer (CFO). Mr. Malkomes joins the executive leadership team to lead Cardior’s financial operations and planning, risk and compliance, investor relations and […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2022. Financial Summary and Highlights1 Revenue of $252.6 million for the quarter decreased 0.2 percent on a reported basis and increased 5.2 percent on a constant-currency basis, as compared […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2022 financial results. “We are proud to share another quarter of strong commercial execution across our business, with excellent EnCompass […]
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today commented on the recent announcement from the Centers for Medicare and Medicaid Services (“CMS”) that it has issued the Medicare Physician Fee […]
IRVINE, Calif., Nov. 1, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement (“ASR”) to repurchase $750 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $1.7 billion of shares in 2022. Under the terms of this ASR, Edwards will receive an initial delivery […]
Study Advances Efforts to Launch CARDIALYTICS Suite of Analytic Tools COPENHAGEN, Denmark, Nov. 2, 2022 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions to enhance clinical decision-making in the EP lab, today announced the investigation of the Signal Complexity™ algorithm designed to visualize and quantify atrial fibrillation (AF) complexity parameters in […]
CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ — ImpediMed Limited (ASX: IPD) reached a milestone of 500,000 patient tests performed with the SOZO® Digital Health Platform. With over 1,100 devices in use globally, the pace of patient testing has accelerated with 100,000 patient tests performed in just the past six months. Product improvements, […]
New data shows Clario has helped more than 2.6 million patients participate in life changing clinical trials for innovative new medicines through decentralized and hybrid technology solutions More than 1000 compounds: Number of potential medicines tested using Clario remote data collection technologies Over 2.6 million patients: Number of participants in Clario DCTs […]
2022 Q3 quarterly HIGHLIGHTS compared to the corresponding period of 2021: Revenue was $14.0 million, same as the prior year period Net income was $3.7 million, or $0.55 per basic share and $0.46 per diluted share, compared to $4.2 million, or $0.61 per basic share and $0.51 per diluted share Cash and cash equivalents at September 30, 2022 increased to $45.5 million from $35.9 million SANTA CLARA, […]
